Lisata Therapeutics, Inc.

Contributing Author

Recent Articles by Lisata Therapeutics, Inc.

Oct-08	Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors LSTA GlobeNewswire
Oct-05	Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly LSTA -14.29% GlobeNewswire
Sep-24	Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026 LSTA GlobeNewswire
Sep-17	Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement LSTA +18.37% GlobeNewswire
Aug-04	Lisata Therapeutics Provides Update Following Termination of Merger Agreement LSTA +9.62% GlobeNewswire
Jun-10	Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc. LSTA GlobeNewswire
Mar-06	Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc. LSTA LSTA +20.57% GlobeNewswire
Jan-27	Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide LSTA +12.29% GlobeNewswire
Jan-21	Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer LSTA +86.57% GlobeNewswire
Nov-06	Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update LSTA LSTA -12.34% GlobeNewswire
Nov-06	Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for 'Overall BioPharma Solution of the Year' LSTA GlobeNewswire
Nov-04	Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent LSTA -7.49% LSTA -5.26% GlobeNewswire
Oct-30	Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025 LSTA GlobeNewswire
Oct-08	Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement LSTA GlobeNewswire
Sep-29	Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial LSTA GlobeNewswire
Sep-02	Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference LSTA GlobeNewswire
Aug-07	Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update LSTA -5.41% LSTA -7.14% GlobeNewswire
Jul-31	Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025 LSTA GlobeNewswire
Jul-17	Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update LSTA -6.23% GlobeNewswire
Jul-15	Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide LSTA GlobeNewswire
Jun-26	Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata's Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer LSTA +16.67% GlobeNewswire
Jun-17	Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development LSTA GlobeNewswire
Jun-11	Lisata Therapeutics to Present at the 2025 BIO International Convention LSTA GlobeNewswire
May-08	Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update LSTA LSTA -11.58% GlobeNewswire

Lisata Therapeutics, Inc.

Recent Articles by Lisata Therapeutics, Inc.

Upgrade your Finviz experience